Responses
Poster Presentations
Rheumatoid arthritis - non-biologic treatment and small molecules
THU0174 A Safety Analysis of Tofacitinib 5 mg Twice Daily Administered as Monotherapy or in Combination with Background Conventional Synthetic Dmards in A Phase 3 Rheumatoid Arthritis Population
Compose a Response to This Article
Other responses
No responses have been published for this article.